Walleye Capital’s Compass Therapeutics CMPX Stock Holding History

Walleye Capital’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-52,478	Closed	-$99.7K	–	4565
2025 Q1	$99.7K	Buy	+52,478	New	+$140K	﹤0.01%	3626

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Walleye Capital's CMPX Position: Q2 2025 in Review

Walleye Capital sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 52,478 shares — an estimated $99.7K sold.

Walleye Capital first reported a position in CMPX in Q1 2025 and held it in 1 quarter. The position peaked at $99.7K in Q1 2025. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

Walleye Capital reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
Walleye Capital sold 52,478 Compass Therapeutics shares in Q2 2025, an estimated $99.7K.
Walleye Capital first reported a position in Compass Therapeutics in Q1 2025 and held it in 1 quarter.
Walleye Capital's Compass Therapeutics position peaked at $99.7K in Q1 2025.
103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.